|
Cellmids' product development program aims to commercialise and clinically validate its early cancer diagnostic assets. In addition the Company is actively seeking collaborations with suitable partners to take advantage of its large therapeutic portfolio for the development of drugs to treat autoimmune and inflammatory diseases as well as ischemia and cancer.
|